ROIV’s mosliciguat advances to phase III in PH-ILD
Phase IIb PHocus study in PH-ILD said mosliciguat delivered a record 56.3% reduction in PVR, with significant and sustained six-minute walk distance improvements, and robust safety and tolerability. Benefits were consistent across subgroups.